Destination XL: Best Comps in Three Years Mask a Deeper Structural Shift

An Inflection, Not a Breakout

When Destination XL Group reported fiscal Q1 earnings on June 3, the headline was a comparable sales decline of 3.8% — still negative, but the best result in three years. CEO Harvey Kanter called it “our strongest quarterly comparable sales result in the past 3 years,” and Peter Stratton, the CFO, echoed that optimism while noting that May comps were running in the “-5% to 6%” range. The market has taken notice: the stock is up 21.9% over the last 90 days, though it remains 93% below its 2021 peak. This is a company at an inflection point — not yet a breakout, but with a plan that is beginning to show life.

The improvement is real, but the underlying drivers are a mix of company-specific initiatives and macro headwinds. Kanter attributed the better comps to “the company specific initiatives which we have been implementing,” but also cited “broader macroeconomic pressure on consumer confidence and discretionary spending including the current global conflict, higher fuel costs, and inflation.” The consumer is under pressure, and DXL’s core big-and-tall customer is particularly sensitive to fuel prices and GLP-1-induced body changes. “We also believe the growing impact GLP-1 medications is contributing to structural change in demand within the big and tall category.” — Harvey S. Kanter · 2026-06-03 That’s not a short-term blip; it’s a permanent shift in how the customer shops, and DXL is trying to get ahead of it.

The GLP-1 Conundrum: Risk and Opportunity

GLP-1 is arguably the most defining theme for DXL right now. The company has repeatedly acknowledged that a meaningful portion of its customer base is using these medications, leading to “more dynamic sizing needs over time.” In the prior quarter’s call, Kanter was more candid about the challenge: “We are seeing some customers size out of our size range or at least, competitively, they can shop at Nordstrom… because they are now a 1X as opposed to a 3X or 4X.” — Harvey Kanter, President and Chief Executive Officer · 2026-03-19 The risk is that customers shrink out of DXL’s target range altogether. The opportunity is that they may return once their weight stabilizes — and DXL is positioning itself to capture that return.

The company is broadening assortments into smaller sizes and using customer insights to inform merchandising and reengagement strategies. Kanter framed it as “both a near term challenge and, most importantly, a long term opportunity.” — Harvey S. Kanter · 2026-06-03 This is not a company sitting still; it’s actively adapting to a secular shift. The GLP 1 keyword has been the top ranked in DXL’s trajectory for two consecutive quarters (20261 and 20262), confirming it is now a central strategic theme rather than a passing reference.

Innovation as a Counterweight

DXL is investing in two technology-driven growth levers: use FitMap and AI. FitMap, the proprietary fit technology that DXL has exclusive rights to until 2030, has been rolled out to all 188 stores. More than 100,000 customers have engaged, and the early results are compelling. Kanter quantified the impact: “We are about a 100-basis points, maybe higher in conversion, something like that… the basket is up double digits and… it is not just 10%, it is meaningfully up.” — Harvey S. Kanter · 2026-06-03 The customers who use FitMap show higher conversion, order value, frequency, and lower return rates — a measurable, tangible benefit.

Separately, DXL is embracing AI to enhance product discoverability and prepare for conversational and agent-driven commerce. This is a forward-looking move that could help the company remain relevant as consumer shopping behavior evolves. “We launched new AI initiatives to improve product quality, enrich item level attributes, and strengthen our ability to connect product pricing, and the inventory information across AI enabled platforms.” — Harvey S. Kanter · 2026-06-03 These initiatives may not move the needle in the short term, but they are strategic bets with long-term payoff potential.

While the path over the years has included both progress and volatility, our belief in the underserved addressable market, and in DXL's long term opportunity remains unchanged. It still drives me today and will continue to do so through the very end of my journey here.

Merger, Tariffs, and the Road Ahead

The headline news beyond operations is the pending merger with FullBeauty. On the call, the board announced a comprehensive reevaluation and stated that the existing terms “are not in the best interest of DXL stockholders.” This is a significant pivot — the company is now engaging in “constructive discussions” to determine a better path, leaving the deal’s fate uncertain. Coupled with Kanter’s planned retirement on August 11, 2026, this introduces leadership and strategic uncertainty, even as the business shows signs of stabilization.

On the financial side, tariffs remain a drag. The company submitted a claim for a refund of approximately $4 million and now estimates the full-year gross margin impact at 100 basis points, down from a prior estimate of 150. That’s an improvement, but still a headwind. “If currently enacted rates remain in effect through fiscal 26, and no additional tariffs are imposed, we estimate that the impact of tariffs on gross margin exclusive of any refunds realized will be approximately 100 basis points.” — Peter H. Stratton Jr. · 2026-06-03 The tariff refund claim is a new development, though the outcome remains uncertain.

Fundamentally, DXL remains small — quarterly revenue of $103 million — and deeply unprofitable on a GAAP basis. Net income for the quarter was -$6 million, and the company burned $12.7 million in free cash. Revenue has declined 25% over the past eight years, and the current rebound is still too early to call a turnaround. The fortress balance sheet — no debt and $70 million of availability — provides cushion, but the clock is ticking on the merger and CEO succession.

In sum, DXL’s quarter was about acknowledging a structural shift, doubling down on innovation, and managing a volatile deal process. The improvement in comps is real and encouraging, but the company is still losing money and faces existential questions about its strategic direction. The stock’s recent bounce suggests the market sees the improvements, but the risk remains high. For investors, the next few quarters will be telling: can the company sustain comp momentum, execute on FitMap and AI, and resolve the merger favorably? If yes, this could be the beginning of a genuine turnaround. If not, the current bounce may prove temporary.